Flutic/vilan 100-25mcg Oral Inh(30)

Manufacturer PRASCO LABORATORIES Active Ingredient Fluticasone and Vilanterol(floo TIK a sone & VYE lan ter ol) Pronunciation floo TIK a sone & VYE lan ter ol
It is used to treat COPD (chronic obstructive pulmonary disease).It is used to treat asthma.Do not use this drug to treat intense flare- ups of shortness of breath. Use a rescue inhaler. If you have questions, talk with the doctor.
🏷️
Drug Class
Bronchodilator/Corticosteroid Combination
🧬
Pharmacologic Class
Inhaled Corticosteroid (ICS) / Long-Acting Beta2-Adrenergic Agonist (LABA)
🀰
Pregnancy Category
Category C
βœ…
FDA Approved
May 2013
βš–οΈ
DEA Schedule
Not Controlled

Overview

ℹ️

What is this medicine?

This medication is an inhaler that contains two medicines: a steroid (fluticasone) to reduce inflammation in your lungs and a long-acting bronchodilator (vilanterol) to help open your airways. It's used once a day for long-term control of asthma or COPD. It is NOT for sudden breathing problems or acute attacks.
πŸ“‹

How to Use This Medicine

Proper Use of This Medication

To use this medication correctly, follow your doctor's instructions and read all the information provided. This medication is for inhalation only. Take it at the same time every day, as directed by your doctor or healthcare provider, even if you are feeling well.

Important Handling Instructions

Do not remove the inhaler from its foil tray until you are ready to use it for the first time.
After each use, close the device and only open it when you need to take a dose.
Do not disassemble or wash the device.
Do not use this inhaler with a spacer.
Avoid breathing out into the device.
After each use, rinse your mouth with water, but do not swallow the water. Instead, spit it out.

Using Multiple Inhaled Medications

If you are taking more than one inhaled medication, consult your doctor about which medication to use first.

Storage and Disposal

Store this medication at room temperature in a dry place, away from bathrooms, heat, and sunlight. The inhaler has a dose counter that tracks the number of doses remaining. Dispose of the inhaler when the counter reaches "0", 6 weeks after opening the foil container, or after the expiration date, whichever occurs first.

Missed Dose Instructions

If you miss a dose, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and resume your regular schedule. Do not take two doses at the same time or take extra doses.
πŸ’‘

Lifestyle & Tips

  • Use this medication regularly, once daily, at the same time each day, even if you feel well.
  • Do NOT use this inhaler for sudden breathing problems; always carry a rescue inhaler (e.g., albuterol) for acute symptoms.
  • Rinse your mouth with water and spit it out after each dose to help prevent oral thrush (a fungal infection in the mouth). Do not swallow the water.
  • Do not exceed the prescribed dose (one inhalation per day).
  • Avoid smoking, especially if you have COPD, as it can worsen your condition.
  • Follow up with your doctor regularly to monitor your lung function and overall health.
πŸ’Š

Available Forms & Alternatives

Dosing & Administration

πŸ‘¨β€βš•οΈ

Adult Dosing

Standard Dose: One inhalation (fluticasone furoate 100 mcg and vilanterol 25 mcg) once daily
Dose Range: 100 - 200 mg

Condition-Specific Dosing:

COPD: One inhalation (fluticasone furoate 100 mcg and vilanterol 25 mcg) once daily.
Asthma: One inhalation (fluticasone furoate 100 mcg and vilanterol 25 mcg) once daily. If inadequate response, may increase to 200 mcg/25 mcg once daily.
πŸ‘Ά

Pediatric Dosing

Neonatal: Not established
Infant: Not established
Child: Not established for children under 18 years of age for asthma or COPD.
Adolescent: Not established for children under 18 years of age for asthma or COPD.
βš•οΈ

Dose Adjustments

Renal Impairment:

Mild: No dose adjustment needed.
Moderate: No dose adjustment needed.
Severe: No dose adjustment needed.
Dialysis: No specific recommendations; monitor for adverse effects.

Hepatic Impairment:

Mild: No dose adjustment needed.
Moderate: No dose adjustment needed.
Severe: For severe hepatic impairment, the recommended dosage is BREO ELLIPTA 100/25 mcg once daily. Monitor patients for systemic corticosteroid effects.

Pharmacology

πŸ”¬

Mechanism of Action

Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. It reduces inflammation in the airways, decreasing bronchial hyperreactivity. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates beta2-receptors in the lungs, leading to relaxation of bronchial smooth muscle and bronchodilation. The combination provides both anti-inflammatory and bronchodilatory effects.
πŸ“Š

Pharmacokinetics

Absorption:

Bioavailability: Fluticasone furoate: Low systemic bioavailability (<1% for 100 mcg dose). Vilanterol: Low systemic bioavailability (approximately 27% of inhaled dose).
Tmax: Fluticasone furoate: 0.5-1 hour. Vilanterol: 5-15 minutes.
FoodEffect: Not applicable for inhaled administration.

Distribution:

Vd: Fluticasone furoate: Approximately 16.2 L/kg. Vilanterol: Approximately 165 L.
ProteinBinding: Fluticasone furoate: >99%. Vilanterol: >99%.
CnssPenetration: Limited

Elimination:

HalfLife: Fluticasone furoate: Approximately 24 hours. Vilanterol: Approximately 11 hours.
Clearance: Fluticasone furoate: High systemic clearance (approximately 65.4 L/hr). Vilanterol: High systemic clearance (approximately 108 L/hr).
ExcretionRoute: Primarily fecal (fluticasone furoate: ~90%; vilanterol: ~70%), with minor renal excretion.
Unchanged: Fluticasone furoate: Negligible. Vilanterol: Negligible.
⏱️

Pharmacodynamics

OnsetOfAction: Vilanterol: Within 5-15 minutes.
PeakEffect: Vilanterol: Within 30 minutes. Fluticasone furoate: Full therapeutic effect may take several days to weeks.
DurationOfAction: 24 hours

Safety & Warnings

⚠️

BLACK BOX WARNING

Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large, randomized, placebo-controlled clinical trial in asthma showed that LABA increased the risk of asthma-related death. This finding with salmeterol, a LABA, is considered a class effect of LABA, including vilanterol, one of the active ingredients in BREO ELLIPTA. The safety and effectiveness of BREO ELLIPTA in patients with asthma less than 18 years of age have not been established. BREO ELLIPTA is not indicated for the primary treatment of status asthmaticus or other acute episodes of bronchospasm.
⚠️

Side Effects

Urgent Side Effects: Seek Medical Help Right Away

Although rare, some people may experience severe and potentially life-threatening side effects while taking this medication. If you notice any of the following symptoms, contact your doctor or seek medical attention immediately:

Signs of an allergic reaction: rash, hives, itching, red, swollen, blistered, or peeling skin (with or without fever), wheezing, tightness in the chest or throat, trouble breathing, swallowing, or talking, unusual hoarseness, or swelling of the mouth, face, lips, tongue, or throat
Signs of infection: fever, chills, severe sore throat, ear or sinus pain, cough, increased or changed sputum production, painful urination, mouth sores, or a wound that won't heal
Signs of high blood sugar: confusion, drowsiness, excessive thirst or hunger, frequent urination, flushing, rapid breathing, or fruity-smelling breath
Signs of low potassium levels: muscle pain or weakness, muscle cramps, or an irregular heartbeat
Signs of a weak adrenal gland: severe nausea or vomiting, extreme dizziness or fainting, muscle weakness, fatigue, mood changes, decreased appetite, or weight loss
Signs of high blood pressure: severe headache or dizziness, fainting, or changes in vision
Chest pain or pressure, or a rapid heartbeat
Shakiness or feeling nervous and excitable
Bone pain
Changes in vision, eye pain, or severe eye irritation
Mouth irritation or mouth sores
Redness or white patches in the mouth or throat
Feeling extremely tired or weak

Respiratory Emergency

This medication can cause severe breathing problems, which may be life-threatening. If you experience difficulty breathing, worsening breathing, wheezing, or coughing after taking this medication, use a rescue inhaler and seek medical help immediately.

Other Possible Side Effects

Like all medications, this drug can cause side effects. While many people may not experience any side effects or only minor ones, it's essential to discuss any concerns with your doctor. If you experience any of the following side effects or any other symptoms that bother you or don't go away, contact your doctor:

Headache
Runny nose
Nose or throat irritation
Common cold symptoms
Flu-like symptoms
Voice changes
Back pain
* Joint pain

This is not an exhaustive list of possible side effects. If you have questions or concerns, consult your doctor. You can also report side effects to the FDA at 1-800-332-1088 or online at https://www.fda.gov/medwatch.
🚨

Seek Immediate Medical Attention If You Experience:

  • Worsening breathing or increased need for your rescue inhaler
  • Chest pain or rapid heart rate
  • Severe allergic reactions (rash, hives, swelling of face/mouth/tongue, difficulty breathing)
  • Signs of infection (fever, chills, increased cough, change in sputum color/amount)
  • New or worsening eye problems (blurred vision, eye pain, halos around lights)
  • Signs of adrenal insufficiency (fatigue, weakness, nausea, vomiting, low blood pressure)
  • Unusual bruising or skin thinning
  • Muscle cramps or weakness
πŸ“‹

Before Using This Medicine

Before taking this medication, it is essential to inform your doctor about the following:

Any allergies you have, including allergies to this drug, its components, or other substances, such as foods or medications. Be sure to describe the allergic reaction you experienced, including any symptoms that occurred.
If you have a milk allergy, as this may be relevant to your treatment.
* If you are currently taking another medication that is similar to this one. If you are unsure, consult your doctor or pharmacist for guidance.

Please note that this is not an exhaustive list of all potential interactions with this medication. To ensure your safety, it is crucial to disclose all of your medications, including prescription and over-the-counter drugs, natural products, and vitamins, as well as any health problems you may have. Your doctor and pharmacist need this information to determine whether it is safe for you to take this medication in conjunction with your other treatments. Never start, stop, or modify the dosage of any medication without first consulting your doctor.
⚠️

Precautions & Cautions

Important Warnings and Cautions for Patients Taking This Medication

It is essential to inform all your healthcare providers, including doctors, nurses, pharmacists, and dentists, that you are taking this medication.

Diabetes and Blood Sugar Control
If you have diabetes (high blood sugar), this medication may cause your blood sugar levels to rise. Consult your doctor about how to manage your blood sugar levels effectively.

Respiratory Problems
If your breathing problems worsen, your rescue inhaler is not working as well as it should, or you need to use it more frequently, contact your doctor immediately.

Dosage and Administration
Do not exceed the recommended dose or use this medication more often than prescribed. Taking too much of this type of medication can be fatal. Consult your doctor if you have any concerns.

Transitioning from Oral Steroids
When switching from an oral steroid to another form of steroid, you may experience severe and potentially life-threatening side effects, including weakness, fatigue, dizziness, nausea, vomiting, confusion, or low blood sugar. If you experience any of these symptoms, contact your doctor immediately.

Stressful Situations
If you have a severe injury, undergo surgery, or develop an infection, you may require additional doses of oral steroids to help your body cope with the stress. Carry a warning card indicating that you may need extra steroids in these situations.

Long-term Use and Eye Health
Prolonged use of this medication may increase your risk of developing cataracts or glaucoma. Consult your doctor about this risk, and schedule regular eye exams as recommended.

Bone Health
Long-term use of this medication may also lead to osteoporosis (weak bones). Discuss your risk factors with your doctor, and undergo bone density tests as advised.

Infection Risk
You may be more susceptible to infections while taking this medication. To minimize this risk, wash your hands frequently, and avoid close contact with people who have infections, colds, or flu.

Chickenpox and Measles
If you have not had chickenpox or measles before, avoid exposure to these diseases, as they can be severe or even fatal in people taking steroid medications like this one. If you have been exposed, consult your doctor immediately.

Growth and Development in Children and Teens
This medication may affect growth in children and adolescents. Regular growth checks may be necessary, and your doctor will discuss this with you.

Pregnancy and Breastfeeding
If you are pregnant, plan to become pregnant, or are breastfeeding, consult your doctor to discuss the benefits and risks of this medication for you and your baby.

COPD and Pneumonia Risk
If you have chronic obstructive pulmonary disease (COPD), you are at a higher risk of developing pneumonia, which can be severe or even fatal. This medication may also increase your risk of pneumonia and hospitalization due to pneumonia. Discuss this risk with your doctor.
πŸ†˜

Overdose Information

Overdose Symptoms:

  • Excessive beta-adrenergic stimulation (e.g., tachycardia, palpitations, tremors, headache, nausea, dizziness, hypokalemia, hyperglycemia)
  • Systemic corticosteroid effects (e.g., Cushingoid features, adrenal suppression, hyperglycemia)

What to Do:

Seek immediate medical attention or call a poison control center (1-800-222-1222). Treatment is supportive and symptomatic. Consider cardioselective beta-blockers for cardiovascular effects, but use with extreme caution in patients with bronchospasm.

Drug Interactions

πŸ”΄

Major Interactions

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin, itraconazole, atazanavir, indinavir, nelfinavir, saquinavir, telithromycin): May significantly increase systemic exposure to fluticasone furoate and vilanterol, leading to increased risk of systemic corticosteroid effects (e.g., Cushing's syndrome, adrenal suppression) and cardiovascular adverse effects (e.g., QTc prolongation, tachycardia) from vilanterol. Co-administration is not recommended.
  • Other long-acting beta2-adrenergic agonists (LABAs): Concomitant use is not recommended as it may lead to an overdose of LABA.
🟑

Moderate Interactions

  • Non-selective beta-blockers (e.g., propranolol): May antagonize the bronchodilatory effect of vilanterol and can produce severe bronchospasm in patients with asthma or COPD. Use with caution, and only if no suitable alternative.
  • Diuretics (e.g., thiazide diuretics, loop diuretics): ECG changes and/or hypokalemia may result from beta-agonists, especially at higher doses. The hypokalemic effect of diuretics may be acutely worsened by beta-agonists. Use with caution.
  • Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs): May potentiate the effect of vilanterol on the cardiovascular system. Use with extreme caution, or consider alternative therapy.

Monitoring

πŸ”¬

Baseline Monitoring

Pulmonary Function Tests (FEV1)

Rationale: To establish baseline lung function and assess disease severity.

Timing: Prior to initiation of therapy.

Ophthalmologic exam (for glaucoma/cataracts)

Rationale: Long-term ICS use can increase risk of glaucoma and cataracts.

Timing: Prior to initiation, especially in patients with risk factors.

Bone Mineral Density (BMD)

Rationale: Long-term ICS use can affect bone density.

Timing: Prior to initiation, especially in patients with risk factors for osteoporosis.

πŸ“Š

Routine Monitoring

Pulmonary Function Tests (FEV1)

Frequency: Periodically (e.g., every 6-12 months or as clinically indicated)

Target: Improvement or stabilization of lung function.

Action Threshold: Worsening FEV1 or lack of improvement may indicate inadequate control or need for re-evaluation.

Symptoms of asthma/COPD control

Frequency: At each visit

Target: Reduced frequency of symptoms, decreased rescue inhaler use, improved quality of life.

Action Threshold: Increased symptoms, increased rescue inhaler use, nocturnal awakenings, or exacerbations.

Adverse effects (e.g., oral candidiasis, pneumonia, systemic corticosteroid effects, cardiovascular effects)

Frequency: At each visit

Target: Absence or minimal adverse effects.

Action Threshold: Presence of oral thrush, signs of infection (fever, increased cough, sputum), vision changes, muscle weakness, easy bruising, palpitations, tremors.

Growth in pediatric patients (if applicable)

Frequency: Regularly (e.g., every 3-6 months)

Target: Normal growth velocity.

Action Threshold: Growth retardation.

πŸ‘οΈ

Symptom Monitoring

  • Worsening shortness of breath
  • Increased need for rescue inhaler (e.g., albuterol)
  • Chest tightness or pain
  • Wheezing
  • Signs of oral thrush (white patches in mouth/throat)
  • Signs of infection (fever, chills, increased cough, change in sputum color/amount)
  • Vision changes (blurred vision, halos around lights)
  • Palpitations or rapid heart rate
  • Tremors
  • Muscle cramps or weakness

Special Patient Groups

🀰

Pregnancy

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Poorly controlled asthma in pregnancy poses risks to both mother and fetus. There are no adequate and well-controlled studies in pregnant women.

Trimester-Specific Risks:

First Trimester: Limited data, but generally, the lowest effective dose should be used.
Second Trimester: Limited data, but generally, the lowest effective dose should be used.
Third Trimester: Limited data, but generally, the lowest effective dose should be used. Monitor for signs of labor inhibition or neonatal adverse effects from LABA.
🀱

Lactation

It is unknown if fluticasone furoate or vilanterol are excreted in human milk. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition. Use with caution.

Infant Risk: Risk is generally low due to low systemic absorption, but potential for infant exposure to corticosteroids and beta-agonists exists. Monitor for signs of systemic corticosteroid effects or beta-agonist effects in the infant.
πŸ‘Ά

Pediatric Use

Not approved for children under 18 years of age for asthma or COPD. Long-term use of inhaled corticosteroids may affect growth velocity in children and adolescents; monitor growth.

πŸ‘΄

Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out. Monitor for comorbidities and potential increased susceptibility to adverse effects.

Clinical Information

πŸ’Ž

Clinical Pearls

  • Breo Ellipta is a once-daily maintenance treatment and should not be used for acute bronchospasm.
  • Patients should be instructed to rinse their mouth with water and spit after each dose to reduce the risk of oral candidiasis.
  • The Ellipta inhaler device is breath-actuated and does not require shaking or priming.
  • Monitor patients with COPD for pneumonia, as ICS use may increase this risk.
  • Caution is advised in patients with cardiovascular disorders, seizure disorders, thyrotoxicosis, or diabetes mellitus due to the LABA component.
  • Patients should be advised not to stop therapy abruptly without consulting their physician, especially if they have been on high doses for prolonged periods, due to the risk of adrenal insufficiency.
πŸ”„

Alternative Therapies

  • Inhaled Corticosteroid (ICS) monotherapy (e.g., fluticasone furoate, budesonide)
  • Long-Acting Muscarinic Antagonist (LAMA) monotherapy (e.g., tiotropium, umeclidinium)
  • Short-Acting Beta2-Adrenergic Agonists (SABAs) for rescue (e.g., albuterol)
  • Oral corticosteroids (for exacerbations or severe disease)
  • Phosphodiesterase-4 (PDE4) inhibitors (e.g., roflumilast for severe COPD)
πŸ’°

Cost & Coverage

Average Cost: Varies widely, typically $300-$500 per 30 doses
Insurance Coverage: Tier 2 or Tier 3 (Preferred or Non-Preferred Brand)
πŸ“š

General Drug Facts

If your symptoms or health issues persist or worsen, it is essential to contact your doctor for further guidance. To ensure your safety, never share your medication with others or take someone else's medication. Some medications may come with an additional patient information leaflet, so it's a good idea to check with your pharmacist for more information. If you have any questions or concerns about this medication, don't hesitate to discuss them with your doctor, nurse, pharmacist, or other healthcare provider. In the event of a suspected overdose, immediately call your local poison control center or seek emergency medical attention. When seeking help, be prepared to provide details about the medication, including the amount taken and the time it happened, to facilitate prompt and effective treatment.